ES2064613T3 - Produccion de agentes citotoxicos. - Google Patents

Produccion de agentes citotoxicos.

Info

Publication number
ES2064613T3
ES2064613T3 ES90301072T ES90301072T ES2064613T3 ES 2064613 T3 ES2064613 T3 ES 2064613T3 ES 90301072 T ES90301072 T ES 90301072T ES 90301072 T ES90301072 T ES 90301072T ES 2064613 T3 ES2064613 T3 ES 2064613T3
Authority
ES
Spain
Prior art keywords
production
cytotoxic agents
cytotoxic agent
antibody
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301072T
Other languages
English (en)
Inventor
Victor John Chen
Louis Nickolaus Jungheim
Damon Lawrence Meyer
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Eli Lilly and Co
Original Assignee
Hybritech Inc
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc, Eli Lilly and Co filed Critical Hybritech Inc
Application granted granted Critical
Publication of ES2064613T3 publication Critical patent/ES2064613T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE PROVEEN UNOS MEDIOS PARA ADMINISTRAR UN AGENTE CITOTOXICO, EL CUAL SE USA EN EL TRATAMIENTO DE ENFERMEDADES NEOPLASICAS. EN PARTICULAR, SE DESCUBREN ANTICUERPOS-ENZIMA CONJUGADOS Y COMPUESTOS DE AGENTES DE SUBSTRATO CITOTOXICO.
ES90301072T 1989-02-02 1990-02-01 Produccion de agentes citotoxicos. Expired - Lifetime ES2064613T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30582489A 1989-02-02 1989-02-02
US30590089A 1989-02-02 1989-02-02

Publications (1)

Publication Number Publication Date
ES2064613T3 true ES2064613T3 (es) 1995-02-01

Family

ID=26974812

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90301072T Expired - Lifetime ES2064613T3 (es) 1989-02-02 1990-02-01 Produccion de agentes citotoxicos.

Country Status (7)

Country Link
EP (1) EP0382411B1 (es)
JP (1) JPH02247164A (es)
AT (1) ATE114974T1 (es)
AU (2) AU633867B2 (es)
CA (1) CA2009071A1 (es)
DE (1) DE69014666T2 (es)
ES (1) ES2064613T3 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
DE68928946T2 (de) * 1989-12-11 1999-10-21 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
AU634921B2 (en) * 1990-12-25 1993-03-04 Ohgen Research Laboratories Ltd. Deacetylcolchicine derivatives
WO1993017707A1 (en) * 1992-03-04 1993-09-16 Akzo N.V. In vivo binding pair pretargeting
WO1994001137A1 (en) * 1992-07-06 1994-01-20 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
JPH08325270A (ja) * 1995-05-31 1996-12-10 Bristol Myers Squibb Co β−ラクタマーゼに対するポリマープロドラッグおよびその使用
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP5130530B2 (ja) * 2005-12-19 2013-01-30 国立大学法人 東京大学 光増感用化合物
CN114086260B (zh) * 2021-12-07 2024-08-20 上海药明康德新药开发有限公司 利用DNA编码化合物库技术制备On-DNA 1,3,4-噁二唑类化合物的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376767A (en) * 1981-01-02 1983-03-15 Merck & Co., Inc. Pyridylmethyl esters of selected bio-affecting carboxylic acids
DE3271892D1 (en) * 1981-09-18 1986-08-07 Kureha Chemical Ind Co Ltd Cephalosporin derivatives
ZA874696B (en) * 1986-07-03 1988-01-04 F. Hoffmann-La Roche & Co. Aktiengesellschaft Acyl derivatives
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5006652A (en) * 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten

Also Published As

Publication number Publication date
JPH02247164A (ja) 1990-10-02
ATE114974T1 (de) 1994-12-15
DE69014666D1 (de) 1995-01-19
EP0382411A2 (en) 1990-08-16
AU4894890A (en) 1990-08-09
CA2009071A1 (en) 1990-08-02
EP0382411B1 (en) 1994-12-07
DE69014666T2 (de) 1995-05-04
EP0382411A3 (en) 1992-01-15
AU633867B2 (en) 1993-02-11
AU3026192A (en) 1993-02-25

Similar Documents

Publication Publication Date Title
TW224942B (es)
ES2064613T3 (es) Produccion de agentes citotoxicos.
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
ATE139531T1 (de) Arylsubstituierte rhodaninderivate
GR3019760T3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
DK0668762T3 (da) Isobytenyl-substituerede taxaner og farmaceutiske præparater deraf
AU6477890A (en) Glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof incombination with functionalized tumor-specific enzyme conjugates
GR3018674T3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
FI901866A0 (fi) Substituerade disulfidderivat med antitumoer- och antibakteriell effekt, vilka framstaells fraon foereningar med en metyltritiogrupp, och maolsoekande former daerav.
SE8900875L (sv) Osteoporosbehandling
ATE69235T1 (de) Erythromycin-a-derivate, modifiziert in position- c-12.
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DK0579939T3 (da) Phospholipidderivater
ES2059882T3 (es) Preparacion de la sustancia fr 115224 para administracion parenteral.
CS318690A3 (en) Pharmaceutical composition usable for depression therapy
FI895005A0 (fi) Immunotoxiner foer behandling och profylax av autoimmuna sjukdomar.
FI920553A0 (fi) Menetelmä lääkeaineina käyttökelpoisten kynureenihapon johdannaisten valmistamiseksi
ATE90565T1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
NO900731L (no) Boelgelengde-spesifikke cytotoksiske midler.
FI953708A0 (fi) Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi
NO904235D0 (no) Forbedret cytotoksisk terapi.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 382411

Country of ref document: ES